Biomarin awaits pivotal data on one of its growth drivers, while Apellis seeks to take off on Pegasus.
Which deals accidentally brought in the biggest biopharma blockbusters? A new analysis by Vantage reveals all.
Instead of tinkering with early-stage genome editing deals like this week's agreement with Bluebird, Novo Nordisk should make a decisive move in haemophilia.
Novo Nordisk took an early step towards genome editing with yesterday’s Bluebird tie-up, and isn’t ruling out a move into conventional gene therapies.
Orphan status for its haemophilia cell therapy and buy-in from Lilly on its diabetes project are good signs for Sigilon, but research is still very early.
Planned divestment of Celgene’s psoriasis blockbuster means instant cashback for Bristol, a result the markets see as a win-win-win.
Spending $95m to speed up the anaemia project’s path to approval could be worth the investment for Astrazeneca.
Sangamo is slowly building a case for SB-525 over Biomarin’s valrox.
Three-year data from Biomarin’s haemophilia A gene therapy fail to quash concerns about durability, but the company insists that the results are good enough to file on.